{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:41:14Z","timestamp":1792813274232,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.prp.2026.156455","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:52:51Z","timestamp":1774425171000},"page":"156455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Non-viral and mRNA-based strategies for next-generation CAR-T cell therapy"],"prefix":"10.1016","volume":"282","author":[{"given":"Taiping","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzheng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.prp.2026.156455_bib1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2026.156455_bib2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.prp.2026.156455_bib3","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.prp.2026.156455_bib4","first-page":"377","article-title":"Rationally designed approaches to augment CAR-T therapy for solid tumor treatment","volume":"33","author":"Zhu","year":"2024","journal-title":"Bioact. Mater."},{"issue":"2","key":"10.1016\/j.prp.2026.156455_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"issue":"8","key":"10.1016\/j.prp.2026.156455_bib6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.prp.2026.156455_bib7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"issue":"7952","key":"10.1016\/j.prp.2026.156455_bib8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.prp.2026.156455_bib9","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.cell.2022.03.023","article-title":"Modular design of synthetic receptors for programmed gene regulation in cell therapies","volume":"185","author":"Zhu","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156455_bib10","doi-asserted-by":"crossref","unstructured":"Allen, G.M., et al., Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science (New York, N.Y.), 2022. 378(6625): p. eaba1624.","DOI":"10.1126\/science.aba1624"},{"key":"10.1016\/j.prp.2026.156455_bib11","doi-asserted-by":"crossref","unstructured":"Reddy, N.R., et al., Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs. Science (New York, N.Y.), 2024. 386(6726): p. eadl4793.","DOI":"10.1126\/science.adl4793"},{"issue":"3","key":"10.1016\/j.prp.2026.156455_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.prp.2026.156455_bib13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2016","journal-title":"Mol. Ther. Methods & Clin. Dev."},{"key":"10.1016\/j.prp.2026.156455_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867013","article-title":"The past, present, and future of non-viral CAR T cells","volume":"13","author":"Moretti","year":"2022","journal-title":"Front Immunol."},{"issue":"43","key":"10.1016\/j.prp.2026.156455_bib15","article-title":"High cost of chimeric antigen receptor T-cells: challenges and solutions","author":"Cliff","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book. Am. Soc. Clin. Oncol. Annu. Meet."},{"issue":"7","key":"10.1016\/j.prp.2026.156455_bib16","doi-asserted-by":"crossref","first-page":"404.e1","DOI":"10.1016\/j.jtct.2022.03.021","article-title":"Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor t cell therapy in the United States","volume":"28","author":"Keating","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.prp.2026.156455_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217083","article-title":"The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: mystery of the Sphinx?","volume":"597","author":"Zhou","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2026.156455_bib18","doi-asserted-by":"crossref","unstructured":"FDA Investigating CAR-Related T-cell Malignancies. Cancer Discovery, 2024, 14(1): pp. 9-10..","DOI":"10.1158\/2159-8290.CD-NB2023-0091"},{"issue":"22","key":"10.1016\/j.prp.2026.156455_bib19","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.prp.2026.156455_bib20","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41417-025-00931-7","article-title":"Barriers and solutions for CAR-T therapy in solid tumors","volume":"32","author":"Tu","year":"2025","journal-title":"Cancer Gene Ther."},{"issue":"7","key":"10.1016\/j.prp.2026.156455_bib21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.prp.2026.156455_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.prp.2026.156455_bib23","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"Vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.prp.2026.156455_bib24","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.prp.2026.156455_bib25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156455_bib26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-bioeng-070620-033348","article-title":"Situ programming of CAR T cells","volume":"23","author":"Parayath","year":"2021","journal-title":"Annu. Rev. Biomed. Eng."},{"issue":"5","key":"10.1016\/j.prp.2026.156455_bib27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41575-022-00729-0","article-title":"Gene therapy for liver diseases - progress and challenges","volume":"20","author":"Zabaleta","year":"2023","journal-title":"Nat. Rev. Gastroenterol. & Hepatol."},{"issue":"11","key":"10.1016\/j.prp.2026.156455_bib28","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","article-title":"Unlocking the promise of mRNA therapeutics","volume":"40","author":"Rohner","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.prp.2026.156455_bib29","doi-asserted-by":"crossref","first-page":"e008417.","DOI":"10.1136\/jitc-2023-008417","article-title":"Stealth transgenes enable CAR-T cells to evade host immune responses","volume":"12","author":"Grauwet","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2026.156455_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114000","article-title":"Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic","volume":"179","author":"Jain","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.prp.2026.156455_bib31","article-title":"Cap 1 messenger RNA synthesis with co-transcriptional CleanCap\u00ae analog by in vitro transcription","volume":"1","author":"Henderson","year":"2021","journal-title":"Curr. Protoc."},{"issue":"4","key":"10.1016\/j.prp.2026.156455_bib32","article-title":"pEVL: a linear plasmid for generating mRNA IVT templates with extended encoded Poly(A) sequences","volume":"5","author":"Grier","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"5","key":"10.1016\/j.prp.2026.156455_bib33","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood.V66.5.1149.1149","article-title":"Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes","volume":"66","author":"Ross","year":"1985","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.prp.2026.156455_bib34","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.prp.2026.156455_bib35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.prp.2026.156455_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"11","key":"10.1016\/j.prp.2026.156455_bib37","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.3390\/ijms26115118","article-title":"The potential of extracellular vesicle-mediated spread of self-amplifying RNA and a way to mitigate it","volume":"26","author":"Federico","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156455_bib38","doi-asserted-by":"crossref","unstructured":"Zhang, H., et al., Deep generative models design mRNA sequences with enhanced translational capacity and stability. Science (New York, N.Y.), 2025. 390(6773): p. eadr8470.","DOI":"10.1126\/science.adr8470"},{"issue":"2","key":"10.1016\/j.prp.2026.156455_bib39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0006-3495(91)82054-9","article-title":"Electroporation of cell membranes","volume":"60","author":"Tsong","year":"1991","journal-title":"Biophys. J."},{"issue":"22","key":"10.1016\/j.prp.2026.156455_bib40","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.prp.2026.156455_bib41","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1021\/acs.chemrev.7b00678","article-title":"Intracellular delivery by membrane disruption: mechanisms, strategies, and concepts","volume":"118","author":"Stewart","year":"2018","journal-title":"Chem. Rev."},{"issue":"18","key":"10.1016\/j.prp.2026.156455_bib42","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1039\/C9LC00458K","article-title":"Acoustophoretic rapid media exchange and continuous-flow electrotransfection of primary human T cells for applications in automated cellular therapy manufacturing","volume":"19","author":"Hsi","year":"2019","journal-title":"Lab a Chip"},{"issue":"19","key":"10.1016\/j.prp.2026.156455_bib43","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1039\/D1LC00219H","article-title":"mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells","volume":"21","author":"Jayasooriya","year":"2021","journal-title":"Lab Chip"},{"key":"10.1016\/j.prp.2026.156455_bib44","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jconrel.2017.08.002","article-title":"Comparing photoporation and nucleofection for delivery of small interfering RNA to cytotoxic T cells","volume":"267","author":"Wayteck","year":"2017","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"1","key":"10.1016\/j.prp.2026.156455_bib45","first-page":"185","article-title":"Intracellular delivery of mRNA in adherent and suspension cells by vapor nanobubble photoporation","volume":"12","author":"Raes","year":"2020","journal-title":"Nanomicro Lett."},{"issue":"28","key":"10.1016\/j.prp.2026.156455_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202102472","article-title":"Photoporation with biodegradable polydopamine nanosensitizers enables safe and efficient delivery of mRNA in human T cells","volume":"31","author":"Harizaj","year":"2021","journal-title":"Adv. Funct. Mater."},{"issue":"11","key":"10.1016\/j.prp.2026.156455_bib47","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/s41565-021-00976-3","article-title":"Photothermal nanofibres enable safe engineering of therapeutic cells","volume":"16","author":"Xiong","year":"2021","journal-title":"Nat. Nanotechnol."},{"issue":"47","key":"10.1016\/j.prp.2026.156455_bib48","article-title":"Cellular deformations induced by conical silicon nanowire arrays facilitate gene delivery","volume":"15","author":"Chen","year":"2019","journal-title":"Small (Weinh. Der Bergstr. Ger. )"},{"issue":"10","key":"10.1016\/j.prp.2026.156455_bib49","doi-asserted-by":"crossref","first-page":"eaat8131","DOI":"10.1126\/sciadv.aat8131","article-title":"Universal intracellular biomolecule delivery with precise dosage control","volume":"4","author":"Cao","year":"2018","journal-title":"Sci. Adv."},{"issue":"12","key":"10.1016\/j.prp.2026.156455_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201807795","article-title":"Self-powered intracellular drug delivery by a biomechanical energy-driven triboelectric nanogenerator","volume":"31","author":"Liu","year":"2019","journal-title":"Adv. Mater. (Deerfield Beach Fla. )"},{"issue":"44","key":"10.1016\/j.prp.2026.156455_bib51","article-title":"Engineering efficient CAR-T cells via electroactive nanoinjection","volume":"35","author":"Shokouhi","year":"2023","journal-title":"Adv. Mater. (Deerfield Beach Fla. )"},{"key":"10.1016\/j.prp.2026.156455_bib52","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mattod.2023.02.009","article-title":"Efficient non-viral CAR-T cell generation via silicon-nanotube-mediated transfection","volume":"63","author":"Chen","year":"2023","journal-title":"Mater. Today"},{"issue":"9","key":"10.1016\/j.prp.2026.156455_bib53","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","article-title":"The 60-year evolution of lipid nanoparticles for nucleic acid delivery","volume":"23","author":"Cullis","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.prp.2026.156455_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.prp.2026.156455_bib55","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1021\/acs.bioconjchem.0c00366","article-title":"The biomolecular corona of lipid nanoparticles for gene therapy","volume":"31","author":"Francia","year":"2020","journal-title":"Bioconjugate Chem."},{"issue":"45","key":"10.1016\/j.prp.2026.156455_bib56","doi-asserted-by":"crossref","first-page":"21733","DOI":"10.1039\/C9NR09347H","article-title":"On the role of helper lipids in lipid nanoparticle formulations of siRNA","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"issue":"12","key":"10.1016\/j.prp.2026.156455_bib57","article-title":"Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.prp.2026.156455_bib58","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1038\/s41467-022-31993-y","article-title":"Multi-step screening of DNA\/lipid nanoparticles and co-delivery with siRNA to enhance and prolong gene expression","volume":"13","author":"Zhu","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.prp.2026.156455_bib59","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1038\/s41467-022-33157-4","article-title":"Payload distribution and capacity of mRNA lipid nanoparticles","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156455_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101139","article-title":"Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering","volume":"31","author":"Kitte","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"1","key":"10.1016\/j.prp.2026.156455_bib61","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","article-title":"Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells","volume":"22","author":"Billingsley","year":"2022","journal-title":"Nano Lett."},{"issue":"26","key":"10.1016\/j.prp.2026.156455_bib62","article-title":"Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy","volume":"36","author":"Metzloff","year":"2024","journal-title":"Adv. Mater."},{"issue":"10","key":"10.1016\/j.prp.2026.156455_bib63","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/s41565-025-01975-4","article-title":"Designing lipid nanoparticles using a transformer-based neural network","volume":"20","author":"Chan","year":"2025","journal-title":"Nat. Nanotechnol."},{"issue":"9","key":"10.1016\/j.prp.2026.156455_bib64","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.ymthe.2024.02.025","article-title":"Therapeutic potential of RNA-enriched extracellular vesicles: The next generation in RNA delivery via biogenic nanoparticles","volume":"32","author":"Muskan","year":"2024","journal-title":"Mo. Ther. J. Am. Soc. Gene Ther."},{"issue":"6","key":"10.1016\/j.prp.2026.156455_bib65","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jcyt.2023.01.005","article-title":"Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering","volume":"25","author":"Si","year":"2023","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.prp.2026.156455_bib66","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharm. Sci."},{"issue":"1","key":"10.1016\/j.prp.2026.156455_bib67","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1021\/acs.accounts.1c00601","article-title":"Non-liver mRNA Delivery","volume":"55","author":"Loughrey","year":"2022","journal-title":"Acc. Chem. Res."},{"issue":"1-2","key":"10.1016\/j.prp.2026.156455_bib68","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jim.2013.04.004","article-title":"vivo depletion of leukocytes and platelets following injection of T cell-specific antibodies into mice","volume":"393","author":"Loubaki","year":"2013","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.prp.2026.156455_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121339","article-title":"situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift","volume":"281","author":"Kheirolomoom","year":"2022","journal-title":"Biomaterials"},{"issue":"6576","key":"10.1016\/j.prp.2026.156455_bib70","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.prp.2026.156455_bib71","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1038\/s41467-022-32281-5","article-title":"Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo","volume":"13","author":"Ni","year":"2022","journal-title":"Nat. Commun."},{"issue":"44","key":"10.1016\/j.prp.2026.156455_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202310395","article-title":"Spleen SORT LNP Generated in situ CAR T Cells Extend Survival in a Mouse Model of Lymphoreplete B Cell Lymphoma","volume":"62","author":"\u00c1lvarez-Benedicto","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"issue":"2","key":"10.1016\/j.prp.2026.156455_bib73","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jconrel.2011.10.005","article-title":"Polymersomes for drug delivery: design, formation and characterization","volume":"161","author":"Lee","year":"2012","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"1","key":"10.1016\/j.prp.2026.156455_bib74","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156455_bib75","doi-asserted-by":"crossref","unstructured":"Hunter, T.L., et al., In vivo CAR T cell generation to treat cancer and autoimmune disease. Science (New York, N.Y.), 2025. 388(6753): p. 1311-1317.","DOI":"10.1126\/science.ads8473"},{"issue":"24","key":"10.1016\/j.prp.2026.156455_bib76","doi-asserted-by":"crossref","first-page":"13685","DOI":"10.3390\/ijms252413685","article-title":"Current non-viral-based strategies to manufacture CAR-T Cells","volume":"25","author":"Gehrke","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2026.156455_bib77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s40164-025-00725-5","article-title":"vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies","volume":"14","author":"Chen","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.prp.2026.156455_bib78","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.immuni.2024.10.011","article-title":"CAR T cells in autoimmune disease: On the road to remission","volume":"57","author":"Schett","year":"2024","journal-title":"Immunity"},{"issue":"482","key":"10.1016\/j.prp.2026.156455_bib79","doi-asserted-by":"crossref","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.prp.2026.156455_bib80","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours - A case series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.prp.2026.156455_bib81","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2024","journal-title":"Lancet Rheumatol."},{"issue":"1","key":"10.1016\/j.prp.2026.156455_bib82","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","article-title":"Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study","volume":"10","author":"Mao","year":"2024","journal-title":"Cell Discov."},{"issue":"1","key":"10.1016\/j.prp.2026.156455_bib83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","article-title":"A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.prp.2026.156455_bib84","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.prp.2026.156455_bib85","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156455_bib86","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","article-title":"Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy","volume":"14","author":"Gong","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"7965","key":"10.1016\/j.prp.2026.156455_bib87","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-023-06139-9","article-title":"Transfer learning enables predictions in network biology","volume":"618","author":"Theodoris","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.prp.2026.156455_bib88","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.1038\/s41598-023-33941-2","article-title":"Scalable continuous-flow electroporation platform enabling T cell transfection for cellular therapy manufacturing","volume":"13","author":"VanderBurgh","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.prp.2026.156455_bib89","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40820-020-00523-0","article-title":"Intracellular delivery of mRNA in adherent and suspension cells by vapor nanobubble photoporation","volume":"12","author":"Raes","year":"2020","journal-title":"Nano-Micro Lett."},{"issue":"12","key":"10.1016\/j.prp.2026.156455_bib90","doi-asserted-by":"crossref","first-page":"1900133.","DOI":"10.1002\/adtp.201900133","article-title":"Transfection with nanostructure electro-injection is minimally perturbative","volume":"2","author":"Tay","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.prp.2026.156455_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101139","article-title":"Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering","volume":"31","author":"Kitte","year":"2023","journal-title":"Mol. Ther. Methods & Clin. Dev."},{"issue":"11","key":"10.1016\/j.prp.2026.156455_bib92","doi-asserted-by":"crossref","first-page":"17802","DOI":"10.1021\/acsnano.2c08774","article-title":"Exosomes\u2500nature's lipid nanoparticles, a rising star in drug delivery and diagnostics","volume":"16","author":"Tenchov","year":"2022","journal-title":"ACS Nano"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826001068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826001068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:33:13Z","timestamp":1785508393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826001068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":92,"alternative-id":["S0344033826001068"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156455","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-viral and mRNA-based strategies for next-generation CAR-T cell therapy","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156455"}}